Si-Quat by AFFIX Labs (FI)

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$238,021.3
Funder
European Commission
Principal Investigator
N/A
Research Location
N/A
Lead Research Institution
N/A
Research Priority Alignment
N/A

Research Category
Infection prevention and control
Research Subcategory
Barriers, PPE, environmental, animal and vector control measures
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Innovation: Si-Quat is an anti-viral clear coat developed to kill viruses including the pathogen of COVID-19. The coating is able to resist thousands of touches and creates an active layer that is self-sanitizing within minutes. Expected Results: Si-Quat active coating has been developed and tested in the lab. In the coming months SiQuat will be field tested and rolled out commercially. The greater goal of the product is to help communities re-open and make people feel more confident going out working, shopping and dining.

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Development and Validation of the Intimate Partner Violence Workplace Disruptions Assessment (IPV-WDA).

Elucidating directed neural dynamics of scene construction across memory and imagination

Implementing a Novel Resident-Led Peer Support Program for Emergency Medicine Resident Physicians.

Cross-Activity Analysis of CRISPR/Cas9 Editing in Gene Families of <i>Solanum lycopersicum</i> Detected by Long-Read Sequencing.

Creating health systems citizens: enhanced professional identity formation through a para-curricular distinction track in health systems transformation and leadership.

A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.